Page last updated: 2024-10-24

positive regulation of hypersensitivity

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate, or extent of hypersensitivity. [GOC:add]

Positive regulation of hypersensitivity is a complex biological process involving multiple cellular and molecular mechanisms that increase the sensitivity of a cell or organism to a specific stimulus. This heightened responsiveness can be beneficial, allowing for rapid and efficient responses to threats, but can also contribute to the development of hypersensitivity reactions such as allergies and autoimmune diseases.

The process begins with the recognition of a specific antigen, or foreign molecule, by immune system cells. This recognition is typically mediated by antigen-presenting cells (APCs) such as dendritic cells and macrophages, which engulf and process the antigen, presenting it to T cells.

Once the antigen is presented, T cells become activated and differentiate into effector T cells, including Th1, Th2, and Th17 cells. Each subset of effector T cells secretes specific cytokines that orchestrate different immune responses.

Th2 cells, in particular, play a crucial role in the development of hypersensitivity reactions. They secrete cytokines such as IL-4, IL-5, and IL-13, which promote the differentiation of B cells into plasma cells that produce IgE antibodies.

IgE antibodies bind to mast cells and basophils, which are immune cells that reside in tissues. When an antigen binds to IgE bound to these cells, it triggers the release of histamine and other inflammatory mediators. This release leads to the characteristic symptoms of hypersensitivity reactions, including vasodilation, bronchospasm, and mucus secretion.

The positive regulation of hypersensitivity involves multiple factors that enhance the strength and duration of these immune responses. These factors can include:

* **Increased expression of receptors**: Cells involved in hypersensitivity, such as mast cells and T cells, can increase the expression of receptors that bind to antigens or inflammatory mediators, making them more sensitive to these signals.
* **Enhanced cytokine production**: Cells can increase the production of cytokines that promote the differentiation and activation of effector cells, amplifying the immune response.
* **Increased IgE production**: B cells can be stimulated to produce more IgE antibodies, which can bind to more mast cells and basophils, increasing the likelihood of an allergic reaction.
* **Dysregulation of regulatory T cells**: Regulatory T cells (Tregs) normally help to suppress immune responses and prevent hypersensitivity reactions. However, in some cases, the function of Tregs may be impaired, allowing for uncontrolled activation of effector cells.

Understanding the molecular mechanisms underlying the positive regulation of hypersensitivity is crucial for developing effective treatments for allergies and other hypersensitivity disorders. By targeting specific pathways that enhance immune responses, researchers are exploring novel strategies for preventing and managing these conditions.'
"

Proteins (1)

ProteinDefinitionTaxonomy
C-C chemokine receptor type 7A C-C chemokine receptor type 7 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P32248]Homo sapiens (human)

Compounds (2)

CompoundDefinitionClassesRoles
tak 779
cenicriviroccenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH).

cenicriviroc: an inhibitor of HIV-1
aromatic ether;
benzazocine;
diether;
imidazoles;
secondary carboxamide;
sulfoxide
anti-HIV agent;
anti-inflammatory agent;
antirheumatic drug;
chemokine receptor 2 antagonist;
chemokine receptor 5 antagonist